A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will investigate the efficacy and safety of RO4607381 in patients with
coronary heart disease, or CHD risk equivalent. After a pre-randomization phase of 5-12
weeks, patients will be randomized to receive either RO4607381 (900mg po) or placebo po daily
for 24 weeks, with concomitant atorvastatin 10-80mg daily, and changes in cholesterol level
and lipoprotein metabolism will be measured. The anticipated time on study treatment is 3-12
months, and the target sample size is 100-500 individuals.